Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial

Convection enhanced delivery of Rhenium (186Re) Obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial

Abstract Rhenium (186Re) Obisbemeda (186RNL), chelated-186Re encapsulated in nanoliposomes and delivered to brain tumors via convection enhanced delivery (CED), was evaluated in a Phase 1 dose escalation trial (NCT01906385). The primary objective was to determine the maximum tolerated dose (MTD). Se...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew J. Brenner, Toral Patel, Ande Bao, William T. Phillips, Joel E. Michalek, Michael Youssef, Jeffrey S. Weinberg, Carlos Kamiya Matsuoka, Marc H. Hedrick, Norman LaFrance, Melissa Moore, John R. Floyd
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-57263-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-57263-1

Similar Items